Literature DB >> 6684892

Neurologic manifestations of essential thrombocythemia.

J Jabaily, H J Iland, J Laszlo, E W Massey, G B Faguet, J Brière, S A Landaw, A V Pisciotta.   

Abstract

Essential thrombocythemia is a clonal myeloproliferative disorder, characterized predominantly by a markedly elevated platelet count without known cause. We report a case that was recognized during investigation of a transient ischemic attack, and review the neurologic findings in 33 patients with unequivocal essential thrombocythemia under prospective study by the Polycythemia Vera Study Group. Twenty-one patients had neurologic manifestations at some point during their course, including headache (13 patients), paresthesiae (10), posterior cerebral circulatory ischemia (9), anterior cerebral circulatory ischemia (6), visual disturbances (6) and epileptic seizures (2). All patients with neurologic symptoms responded satisfactorily to treatment, although continuous or repeated treatment was often required. Therapeutic recommendations include plateletpheresis for major thrombo-hemorrhagic phenomena, or megakaryocyte suppression with radioactive phosphorus, alkylating agents (such as melphalan), or hydroxyurea; minor symptoms may respond to platelet antiaggregating agents.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6684892     DOI: 10.7326/0003-4819-99-4-513

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  13 in total

1.  Neurological disorders in essential thrombocythemia.

Authors:  Segolene Billot; Eirini G Kouroupi; Johan Le Guilloux; Bruno Cassinat; Caroline Jardin; Thierry Laperche; Pierre Fenaux; Antoine F Carpentier; Jean-Jacques Kiladjian
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  Recombinant interferon-alpha, but not interferon-gamma is effective therapy for essential thrombocythemia.

Authors:  M J Abegg-Werter; J M Raemaekers; B E de Pauw; C Haanen
Journal:  Blut       Date:  1990-01

3.  Benign intracranial hypertension and essential thrombocythaemia.

Authors:  A Esack; G Thompson; H Burmester
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-07       Impact factor: 10.154

Review 4.  Coagulation abnormalities and cerebral infarction.

Authors:  M Greaves
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

5.  Essential thrombocytemia and ischemic stroke: report of six cases.

Authors:  L Casto; M Camerlingo; G Finazzi; B Censori; T Barbui; A Mamoli
Journal:  Ital J Neurol Sci       Date:  1994-10

6.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Authors:  Heinz Gisslinger; Mirjana Gotic; Jerzy Holowiecki; Miroslav Penka; Juergen Thiele; Hans-Michael Kvasnicka; Robert Kralovics; Petro E Petrides
Journal:  Blood       Date:  2013-01-11       Impact factor: 22.113

7.  Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders.

Authors:  H Ludwig; W Linkesch; H Gisslinger; E Fritz; H Sinzinger; T Radaszkiewicz; A Chott; R Flener; M Micksche
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  [Clinical characterization of essential thrombocythemia in comparison with other myeloproliferative diseases and reactive thrombocytoses].

Authors:  M Jahn; B Zönnchen; W Köpcke; R Hehlmann
Journal:  Klin Wochenschr       Date:  1988-03-01

9.  [Megakaryocytic myelosis--clinical aspects, morphology and platelet function].

Authors:  A Hochhaus; D Höche; K Mindner; G Ostermann; M Meyer
Journal:  Klin Wochenschr       Date:  1989-01-20

10.  Cerebral venous thrombosis as presenting sign of myeloproliferative disorders.

Authors:  J Haan; J F Caekebeke; F J van der Meer; A R Wintzen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.